


## Supplementary Figure S8



**Supplementary Figure S8. Additional MPNST analyses for CDK4/6-MEK inhibition plus anti-PD-L1 therapy study.** Wild-type mice bearing *de novo* MPNSTs, initiated by CRISPR editing of *Nf1/Ink4a/Arf* in the sciatic nerve, were treated daily with the indicated therapies. **(A)** Tumor volume measurements show equivalent tumor sizes at the initiation of therapy for all 4 treatment groups. **(B)** Graph of weekly body weights for drug treated mice showing no effect of the treatments. Error bars, SEM. *P* value, One-way ANOVA with Tukey's correction for multiple comparisons.